Back to journals
Academic Journal

Psychedelic Medicine

20 Papers Indexed in Blossom

Data updated

Publication Landscape

How the 20 psychedelic papers Blossom tracks from Psychedelic Medicine line up by year, topic and compound. This is the journal's psychedelic-research output in Blossom's records as of July 2026; its full catalogue is much larger.

How much psychedelic research does Psychedelic Medicine carry?

Sourced

Tracked papers by publication year. Click a year for the running total.

9papers published in 2023

9 published by 2023

Browse papers→

Don't read as the journal's total output: only the 20 of 20 tracked psychedelic papers from Psychedelic Medicine with a recorded publication date are counted, and Blossom tracks only psychedelic-relevant papers, so the full catalogue is much larger. The current year is still filling in.

What does Psychedelic Medicine publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Depressive Disorders
10
Anxiety Disorders
7
Addiction & Substance Use
4
Palliative & End-of-Life Distress
4
Equity and Ethics
4
PTSD
4
Interpersonal Functioning & Social Connectedness
3
Safety & Risk Management
2
Other
12

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not the journal's full catalogue.

Which compounds does Psychedelic Medicine cover?

Sourced

Tracked papers per compound. Orange marks the most-covered compound.

Psilocybin
10
LSD
3
MDMA
2

Don't read shares as adding to 100%: a paper studying several compounds counts once per compound, and placebo comparator arms are not shown. These are the psychedelic-relevant papers Blossom tracks.

Research Footprint

Psychedelic Medicine has 20 tracked papers indexed in Blossom (2023–2026) from 122 authors, most often covering Psilocybin, LSD and MDMA, across Depressive Disorders, Anxiety Disorders and Palliative & End-of-Life Distress.

Published Papers

Paywallmeta

m-DASC: Measuring Subjective Effects of Very Low Doses of Psychedelic Drugs.

This methodological study (n=199) developed a new questionnaire, the micro-dimensional Altered States of Consciousness scale, to measure the subtle subjective effects of very low doses of LSD. The 31-item tool captured four main experience areas and detected effects at 13 and 26 µg, while matching the longer questionnaires closely.

Published
Journal
Psychedelic Medicine
Authors
Griffin-Stolbach, J., Molla, H., Hedeker, D., de Wit, H.
Open Accessindividual

Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions

In a randomised, parallel-group waitlist-controlled exploratory study (n=29) of psychedelic-naïve clergy, two supported psilocybin sessions were well tolerated and produced significant, sustained increases in religious practices, attitudes, perceived leadership effectiveness, and broader psychological wellbeing. These effects persisted up to 16 months and were frequently rated among participants' most spiritually meaningful experiences.

Published
Journal
Psychedelic Medicine
Authors
Griffiths, R. R., Jesse, R., Richards, W. A., Johnson, M. W., Sepeda, N. D., Bossis, A. P., Ross, S.
Open Accessindividual

Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 Study

This Phase I/II study (n=52) tested a group retreat model of psilocybin therapy for people with metastatic cancer and anxiety or depression, using 25 mg psilocybin in a 3-day retreat format. No unattended distress episodes occurred, and anxiety and depression scores fell over 28 days.

Published
Journal
Psychedelic Medicine
Authors
Back, A. L., McGregor, B. A., Thorn, L. L., Baker, K., Gooley, T., Kaelen, M., Harvey, K., Guy, J. M., Myers, S., Perez, J., Thompson, P., Billingsley, L., Sesnon, C.
Paywallindividual

Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study

This secondary analysis (n=52) describes a Phase I/II group psilocybin retreat model for people with metastatic cancer and moderate to severe anxiety or depression, using a secular ritual approach based on rites of passage. It describes a model designed for a 3-day in-person retreat and linked to safety and efficacy outcomes in the trial.

Published
Journal
Psychedelic Medicine
Authors
Back, A. L., McGregor, B. A., Billingsley, L., Blom, D., Callan, G., Myers, S., Guy, J., Kumar, S., Layer, M., Levin, J., Perez, J., Thompson, P., Salmonson, K., Whinney, J., Thorn, L. L.
Paywallindividual

Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression in Bipolar II Disorder

In a subgroup analysis of four adults with treatment-resistant bipolar II disorder, one or two 25 mg psilocybin-assisted psychotherapy sessions produced rapid reductions in depressive symptoms (mean MADRS 32.5 → 20.3 at two weeks, 21.3 at six months). No treatment-emergent mania, hypomania or psychosis was observed, indicating preliminary safety and potential antidepressant efficacy that requires confirmation in larger trials.

Published
Journal
Psychedelic Medicine
Authors
Meshkat, S., Kaczmarek, E., Doyle, Z., Brudner, R. M., Gomes, F. A., Blainey, M. G., Weiglein, G., McIntyre, R. S., Mansur, R. B., Rosenblat, J. D.
Paywallindividual

Evolving Guidelines for the Use of Touch During a Clinical Trial of Group Psilocybin-Assisted Therapy

This technical report (2024) describes the evolving guidelines for facilitator use of touch in a group retreat-based format of psilocybin-assisted therapy. The primary goal is to create a safe and supportive haptic experience during sessions, with a secondary goal of maintaining therapeutic boundaries and responding to participant experiences with empathy.

Published
Journal
Psychedelic Medicine
Authors
Back, A., Myers, S., Guy, J., Perez, J., Thorn, L. L., Mcgregor, B.

Quick Facts

Papers Indexed
20
Publisher
Mary Ann Liebert
Website
Visit